Physician profile
Benjamin M Rogers
NPI 1801023502
$3,708.12
in general payments reported to CMS, 2019-2025
35 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $700 · 2021: $668 · 2022: $393 · 2023: $353 · 2024: $426 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $679.60 | 2019-2025 | |
| Novo Nordisk INC | $651.80 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $400.33 | 2019-2025 | Ubrelvy, Vraylar |
| Janssen Pharmaceuticals, INC | $231.69 | 2019-2022 | |
| Astellas Pharma US INC | $216.57 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $207.09 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.53 | 2019-2024 | Xifaxan |
| Amgen INC. | $110.46 | 2019-2024 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $90.41 | 2019-2023 | Eliquis |
| Glaxosmithkline, LLC. | $71.78 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $69.23 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.01 | 2019-2022 | |
| Medicomp INC | $67.31 | 2024 | Telepatch Cardiac Monitor |
| Xeris Pharmaceuticals, INC. | $65.82 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Eagle Pharmaceuticals, INC. | $64.30 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63.55 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $50.80 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $45.31 | 2019-2020 | |
| Biogen, INC. | $44.36 | 2025 | Leqembi |
| Radius Health, INC. | $34.61 | 2019-2021 | |
| Csl Behring | $32.21 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.62 | 2019-2025 | Trintellix |
| Currax Pharmaceuticals LLC | $30.81 | 2020-2021 | |
| Allergan, INC. | $29.43 | 2020 | |
| Amarin Pharma, INC. | $28.18 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $27.47 | 2024 | Exparel |
| Merck Sharp & Dohme LLC | $27.45 | 2019 | |
| Horizon Therapeutics Plc | $25.41 | 2022 | |
| Medtronic, INC. | $24.76 | 2022 | |
| Braintree Laboratories, INC. | $21.87 | 2023 | Sutab |
| Eisai INC. | $18.97 | 2025 | |
| Corcept Therapeutics | $16.70 | 2021 | |
| Seqirus USA INC | $14.35 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.30 | 2021 | |
| Sumitomo Pharma America, INC. | $12.03 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.